Indian Journal of Animal Research
Chief EditorM. R. Saseendranath
Print ISSN 0367-6722
Online ISSN 0976-0555
NAAS Rating 6.40
SJR 0.233, CiteScore: 0.606
Impact Factor 0.4 (2024)
Chief EditorM. R. Saseendranath
Print ISSN 0367-6722
Online ISSN 0976-0555
NAAS Rating 6.40
SJR 0.233, CiteScore: 0.606
Impact Factor 0.4 (2024)
Effect of Quercetin and Resveratrol on Raftlin, 8-iso Prostaglandin F2alpha Levels in Renal Ischemia-reperfusion Injury
Submitted04-08-2024|
Accepted13-02-2025|
First Online 10-06-2025|
Background: Renal ischemia reperfusion injury (IRI) can be frequently observed in mandatory clinical situations such as organ transplantation, as well as in undesirable clinical scenarios such as embolic, thrombotic causes and hypotensive shock. This damage is an important pathological process that can occur in a wide clinical spectrum, such as acute renal failure and permanent renal failure. The effects of Quercetin and Resveratrol, substances with high antioxidant capacity that may have a positive effect on this pathological process, on renal IRI were examined by looking at Raftlin and 8-iso Prostaglandin F2alpha (8-iso-PGF2a) levels.
Methods: Forty-two male Wistar-albino rats were divided into six groups (Control group; n=7, I/R group; n=7, Sham group; n=7, Quercetin group; n=7, Resveratrol group; n=7, Quercetin and resveratrol group; n=7). Quercetin (100 mg/kg) and resveratrol (100 mg/kg) was administered intragastricly in the treatment group. Only sham group was administered with 0.9% serum physiologic (NaCI). Raftlin and 8-iso-PGF2avalues were measured by ELISA method. In the histopathological examination, the groups were evaluated in terms of hemorrhage, myocardial edema, myocytolysis and polymorphonuclear leukocyte infiltration.
Result: It was observed that both quercetin and resveratrol molecules decreased Raftlin and 8-iso-PGF2a values. The group in which the two molecules were given together had the lowest values and it was determined that this value approached the control group value. Quercetin and resveratrol are thought to have a protective effect on renal IRI.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.